Land: Kanada
Sprache: Englisch
Quelle: Health Canada
NAPROXEN (NAPROXEN SODIUM, NAPROXEN)
APOTEX INC
M01AE02
NAPROXEN
200MG
CAPSULE
NAPROXEN (NAPROXEN SODIUM, NAPROXEN) 200MG
ORAL
100
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0109634009; AHFS:
APPROVED
2019-05-10
Page 1 of 41 PRODUCT MONOGRAPH NAPROXEN CAPSULES 200 MG Naproxen Capsules 200 mg (as free acid and sodium salt) Non-steroidal anti-inflammatory drug Analgesic, Antipyretic APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Submission Control No: 268717 Date of Revision: February 15, 2023 Page 2 of 41 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................................... 3 CONTRAINDICATIONS .............................................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................................. 4 ADVERSE REACTIONS ............................................................................................................... 6 DRUG INTERACTIONS ............................................................................................................... 9 DOSAGE AND ADMINISTRATION ......................................................................................... 12 OVERDOSAGE ........................................................................................................................... 12 ACTION AND CLINICAL PHARMACOLOGY ....................................................................... 12 STORAGE AND STABILITY ..................................................................................................... 14 SPECIAL HANDLING INSTRUCTIONS .................................................................................. 14 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................................ 14 PART II: SCIENTIFIC INFORMATION ............................................................................... 15 PHARMACEUTICAL INFORMATION ........................ Lesen Sie das vollständige Dokument